NCT03586908View on ClinicalTrials.gov

PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 4, 2018

Primary Completion Date

February 27, 2018

Study Completion Date

March 9, 2018

Conditions
Healthy Volunteer
Interventions
DRUG

PHP-201 0.5% ophthalmic solution (topical eye drop)

D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID

Trial Locations (1)

47323

Inje University Busan Baek Hospital, Busan

Sponsors

Lead Sponsor

pH Pharma
All Listed Sponsors
lead

pH Pharma

INDUSTRY

NCT03586908 - PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects | Biotech Hunter | Biotech Hunter